All In Biotech

Drug Trial Radar · NCT01965652

Long Term Safety of Naldemedine

A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy

Last checked: Nov 20, 2026Latest source record: Apr 18, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,246 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,246

Actual

Start

Sep 24, 2013

Primary completion

Jan 12, 2016

Study completion Jan 12, 2016

Sponsor

Lead sponsor
ShionogiIndustry
Sponsor type
Industry
First posted
Oct 18, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the long-term safety of naldemedine for the treatment of constipation due to opioid therapy.

Conditions

  • Opioid-induced Constipation

Interventions

  • NaldemedineDrug

    Naldemedine 0.2 mg tablet taken orally once a day

  • PlaceboDrug

    Placebo tablet taken orally once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse EventsTime frame: From the first dose of study drug up to 14 days after the last dose of study drug (54 weeks).

Locations

186 sites in 16 countries. Site status is shown where the registry gives one.

  • Shionogi Research Site

    Birmingham, Alabama

  • Shionogi Research Site

    Mobile, Alabama

  • Shionogi Research Site

    Chandler, Arizona

  • Shionogi Research Site

    Glendale, Arizona

  • Shionogi Research Site

    Goodyear, Arizona

  • Shionogi Research Site

    Mesa, Arizona

  • Shionogi Research Site

    Phoenix, Arizona

  • Shionogi Research Site

    Tucson, Arizona

  • Shionogi Research Site

    Fountain Valley, California

  • Shionogi Research Site

    Garden Grove, California

  • Shionogi Research Site

    Glendale, California

  • Shionogi Research Site

    Long Beach, California

  • Shionogi Research Site

    Los Angeles, California

  • Shionogi Research Site

    Oceanside, California

  • Shionogi Research Site

    Sacramento, California

  • Shionogi Research Site

    Santa Ana, California

  • Shionogi Research Site

    Upland, California

  • Shionogi Research Site

    Colorado Springs, Colorado

  • Shionogi Research Site

    Boynton Beach, Florida

  • Shionogi Research Site

    Brandon, Florida

  • Shionogi Research Site

    Brooksville, Florida

  • Shionogi Research Site

    Clearwater, Florida

  • Shionogi Research Site

    Fort Myers, Florida

  • Shionogi Research Site

    Jacksonville, Florida

  • Shionogi Research Site

    Lake City, Florida

  • Shionogi Research Site

    Lakeland, Florida

  • Shionogi Research Site

    Orlando, Florida

  • Shionogi Research Site

    South Miami, Florida

  • Shionogi Research Site

    St. Petersburg, Florida

  • Shionogi Research Site

    Tampa, Florida

  • Shionogi Research Site

    Atlanta, Georgia

  • Shionogi Research Site

    Blue Ridge, Georgia

  • Shionogi Research Site

    Decatur, Georgia

  • Shionogi Research Site

    Savannah, Georgia

  • Shionogi Research Site

    Boise, Idaho

  • Shionogi Research Site

    Aurora, Illinois

  • Shionogi Research Site

    Bloomington, Illinois

  • Shionogi Research Site

    Decatur, Illinois

  • Shionogi Research Site

    Rockford, Illinois

  • Shionogi Research Site

    Schaumburg, Illinois

Showing 40 of 186 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.